Investing.com -- Teva Pharmaceutical Industries (NYSE: TEVA ) on Thursday reiterated its financial targets for 2027, which include achieving a 30% operating profit margin.
This comes amid expectations of revenue growth, fueled by innovative product launches and a stable generics business.
The company is aiming for an expansion in its operating margin to 30% by 2027.
In terms of cash flow, Teva projects a free cash flow exceeding $2.7 billion in 2027, and over $3.5 billion by 2030. The firm also plans to reduce its payment of debt down to 2x net leverage.
Teva is set to achieve about $700 million in net savings through modernizing the organization and enhancing operational efficiencies.
The company’s innovative medicines franchise is slated to surpass $5 billion by 2030. This is in line with the company’s long-term strategy of focusing on innovation and efficiency to drive growth and profitability.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.